fbpx

Exits

EpiTherapeutics

Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.

Invested in 2010

Acquired by Gilead in 2015

Based in Foster City, California, USA 

Lundbeckfonden Emerge

Nyheder

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer
25. februar 2020
AFYX Therapeutics Presents Results from Rivelin Clinical Proof of Concept Study in Patients with Vulvar Lichen Sclerosus at the 2019 European Academy of Dermatology and Venereology Congress
10. oktober 2019
23 danske biotek-selskaber på investor-jagt i New York
3. april 2019